ArticleCureus2025
Serum S100-Beta as a Biomarker for Neurological Recovery in Acute Spinal Cord Injury (ASCI): A Prospective Case-Control Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute spinal cord injury (ASCI) leads to severe neurological deficits with limited prognostic biomarkers. However, S100-beta (S100B), a calcium-binding protein, emerges as a beacon of hope, showing potential as a serological marker of ASCI severity and recovery, inspiring further research and exploration in this field.
methodsThis prospective case-control study included 26 patients with ASCI and 26 age- and sex-matched healthy controls. Serum S100B levels were measured using enzyme-linked immunosorbent assay (ELISA) at baseline, two, and six weeks. Neurological recovery was evaluated using the American Spinal Injury Association (ASIA) Impairment Scale.
resultsSerum S100B levels in ASCI patients were significantly higher than controls at baseline (0.95 ± 0.16 µg/L vs. 0.028 ± 0.02 µg/L; p < 0.05) and at two weeks (p < 0.05). Levels normalized after six weeks (p > 0.05). Also, when comparing serum S100B levels among cases, it was higher in paraplegia than in the paraparesis group. Elevated serum S100B levels correlated with greater injury severity and poorer neurological outcomes.
conclusionS100B is a promising biomarker for early ASCI severity and recovery. However, further large-scale studies are required to establish its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.